Min Fang

HTDK Medical Holdings Ltd. operates as an investment holding company. It is principally engaged in providing product commercial solutions in medical device and consumer healthcare product sectors. The company specializes in medical device enterprises which cover the diagnosis, orthopedics, ophthalmology, cardiovascular and other indications. The company was founded on July 9, 2021 and is headquartered on Shanghai, China.

Sichuan Jinxin Fertility Medical Management Co., Ltd. operates fertility centers. The company was founded on September 12, 2016 and is headquartered in Chengdu, China.

Sichuan Jinxin Fertility Medical Management Co., Ltd. operates fertility centers. The company was founded on September 12, 2016 and is headquartered in Chengdu, China.

Part of Warburg Pincus & Company US LLC, Warburg Pincus Investment Consulting Co. Ltd. operates as a venture capital firm. The private company is based in Shanghai, China.

HTDK Medical Holdings Ltd. operates as an investment holding company. It is principally engaged in providing product commercial solutions in medical device and consumer healthcare product sectors. The company specializes in medical device enterprises which cover the diagnosis, orthopedics, ophthalmology, cardiovascular and other indications. The company was founded on July 9, 2021 and is headquartered on Shanghai, China.

InSilico Medicine Hong Kong Ltd. operates as bioinformatics company, which utilizes advances in genomics, big data analysis and deep learning for silico drug discovery and drug repurposing for aging and age-related diseases. The company was founded by Alex Zhavoronkov and is headquartered in Hong Kong.

InSilico Medicine Hong Kong Ltd. operates as bioinformatics company, which utilizes advances in genomics, big data analysis and deep learning for silico drug discovery and drug repurposing for aging and age-related diseases. The company was founded by Alex Zhavoronkov and is headquartered in Hong Kong.

China Biologic Products, Inc. operates as a biopharmaceutical company, which engages in the manufacture and distribution of plasma-based pharmaceutical products and other biological substances. Its products include human albumin, human immunoglobulin for intravenous injection, human Hepatitis B immunoglobulin, human rabies immunoglobulin, human immunoglobulin, human coagulation factor VIII, human prothrombin complex concentrate, and placenta polypeptide. The company was founded on December 20, 1989 and is headquartered in Beijing, China.

EA, Inc. engages in the manufacturing and sale of orthodontic products. Its products include clear orthodontics retainers and aligners. The company was founded in June 2003 and is headquartered in Shanghai, China.

Sichuan Jinxin Fertility Medical Management Co., Ltd. operates fertility centers. The company was founded on September 12, 2016 and is headquartered in Chengdu, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

HTDK Medical Holdings Ltd. operates as an investment holding company. It is principally engaged in providing product commercial solutions in medical device and consumer healthcare product sectors. The company specializes in medical device enterprises which cover the diagnosis, orthopedics, ophthalmology, cardiovascular and other indications. The company was founded on July 9, 2021 and is headquartered on Shanghai, China.

HTDK Medical Holdings Ltd. operates as an investment holding company. It is principally engaged in providing product commercial solutions in medical device and consumer healthcare product sectors. The company specializes in medical device enterprises which cover the diagnosis, orthopedics, ophthalmology, cardiovascular and other indications. The company was founded on July 9, 2021 and is headquartered on Shanghai, China.

HTDK Medical Holdings Ltd. operates as an investment holding company. It is principally engaged in providing product commercial solutions in medical device and consumer healthcare product sectors. The company specializes in medical device enterprises which cover the diagnosis, orthopedics, ophthalmology, cardiovascular and other indications. The company was founded on July 9, 2021 and is headquartered on Shanghai, China.

HTDK Medical Holdings Ltd. operates as an investment holding company. It is principally engaged in providing product commercial solutions in medical device and consumer healthcare product sectors. The company specializes in medical device enterprises which cover the diagnosis, orthopedics, ophthalmology, cardiovascular and other indications. The company was founded on July 9, 2021 and is headquartered on Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

HTDK Medical Holdings Ltd. operates as an investment holding company. It is principally engaged in providing product commercial solutions in medical device and consumer healthcare product sectors. The company specializes in medical device enterprises which cover the diagnosis, orthopedics, ophthalmology, cardiovascular and other indications. The company was founded on July 9, 2021 and is headquartered on Shanghai, China.

HTDK Medical Holdings Ltd. operates as an investment holding company. It is principally engaged in providing product commercial solutions in medical device and consumer healthcare product sectors. The company specializes in medical device enterprises which cover the diagnosis, orthopedics, ophthalmology, cardiovascular and other indications. The company was founded on July 9, 2021 and is headquartered on Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

InSilico Medicine Hong Kong Ltd. operates as bioinformatics company, which utilizes advances in genomics, big data analysis and deep learning for silico drug discovery and drug repurposing for aging and age-related diseases. The company was founded by Alex Zhavoronkov and is headquartered in Hong Kong.

InSilico Medicine Hong Kong Ltd. operates as bioinformatics company, which utilizes advances in genomics, big data analysis and deep learning for silico drug discovery and drug repurposing for aging and age-related diseases. The company was founded by Alex Zhavoronkov and is headquartered in Hong Kong.

HTDK Medical Holdings Ltd. operates as an investment holding company. It is principally engaged in providing product commercial solutions in medical device and consumer healthcare product sectors. The company specializes in medical device enterprises which cover the diagnosis, orthopedics, ophthalmology, cardiovascular and other indications. The company was founded on July 9, 2021 and is headquartered on Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.